Allogene's Cema-cel Trials: Unlocking Major Profit Potential for Investors.

Greetings, fellow investors! Welcome back to ShareTreck. I'm Raj, today I am going to talk about why I think Allogene can make us money. This is because of two news articles in the last 15 days that show progress in their pivotal study for Cema-cel. I also discuss how the current bullishness can moderate as the BLA is further out into 2027.
Meanwhile earlier Pemvidutide was superior only because it did not show muscle loss. Now with additional side effects for Semaglutide, if the FDA approves Pemvidutide, that can catapult Altimmune overnight to top spot in the obesity therapy market.
Well this is my personal opinion, not financial advice.
JOIN THE CHANNEL AS A MEMBER:
Please check out the membership offering and join me in the exciting new chapter for ShareTreck, Thanks for your support so far and looking forward to much more. Use the link below to join or click on the Join button on the bottom left of your screen or copy the link below to your browser address bar and press enter.
/ @sharetreck
Please subscribe: / @sharetreck
The videos in this channel should not be construed as financial advice. Always make sure to do your own due diligence and research.
Please do not trade or invest based on this video. Information provided in this video is not investment advice and is for entertainment purposes only.
In case of coverage of pharma companies, disease and therapy details are derived from news articles and publications by companies or research organizations. I am not a doctor but am only facilitating dissemination of published information.